Ikonisys SA (Euronext Growth Paris: ALIKO), a company specializing in the early and accurate detection of cancers through a unique fully automated solution for medical analysis laboratories, today announces the signing of a distribution agreement with Green Med, a major distributor of medical devices in Panama and Central America. This collaboration is part of a strategic initiative, which aims at bringing innovative cytological and oncological diagnostics to the region, based on four core initiatives.

The first step of the plan focuses on certification and importation of Ikonisys Group’s products into Panama, leveraging the region’s logistical and operational advantages. Panama’s strategic position as a logistics hub will enable streamlined distribution and access to Ikonisys Group’s products across Central America (including Costa Rica, Nicaragua, Honduras, Salvador, Guatemala and Belize).

The second pillar of this initiative involves introducing Liquid-Based Cytology (LBC) technology into Panamanian healthcare facilities, which currently rely solely on traditional cytology methods. Through this agreement, Ikonisys Group aims to modernize diagnostic processes, providing LBC solutions that enhance diagnostic accuracy, improve sample quality, and optimize laboratory workflows.

Furthermore, Ikonisys Group will promote its FISH (Fluorescence In Situ Hybridization) technology to major oncology diagnostic centers nationwide, offering high sensitivity testing for various oncological applications and facilitating early and accurate cancer detection, ultimately improving patient outcomes.

Finally, Ikonisys Group will establish a Temporary Association of Companies (ATI) with local partners to collaborate with the Panamanian government on a bladder cancer mass screening project. This program aims to provide early detection and preventive care for urinary tract diseases, a significant public health concern in the region. Once the trial is validated, this screening program could be applied across the region.

The initial market test will be conducted in Panama, chosen for its strategic location and advanced healthcare infrastructure and will encompass the full product line of Ikonisys Group, serving as a benchmark for subsequent launches across Central America.

“We are thrilled to partner with Green Med and all our participating operators,” stated Alessandro Nosei, General Manager of Hospitex – Ikonisys Group“The initial market test in Panama is a crucial step towards global implementation of our strategy.”

Through this initiative, Ikonisys Group reaffirms its commitment to supporting cancer diagnostic advancements in Panama and bringing cutting-edge diagnostic technology to Latin America, working closely with local institutions to address pressing healthcare needs.

Leave a Reply

Your email address will not be published. Required fields are marked *